Navigation Links
Generex Touts Pipeline Potential of Antigen Express Subsidiary
Date:2/7/2013

platform.  This technology enhances delivery of key target proteins like HER2 for cancer to a critical immune recognition site enhancing immune recognition. The Company has also developed compounds designed for important non-HER2 cancer associated protein targets using the Ii-Key technology platform. These include the melanoma-associated gp100 target, as well as cervical and head-and-neck cancers associated with Human Papilloma Virus (HPV). These compounds have shown significant activity in animal models that has been described in peer-reviewed publications.

In addition to cancer protein targets, the Company has clinically tested Ii-Key-based proteins designed to protect against the potentially pandemic influenza strains H5N1 (avian flu) and H1N1 (swine flu). The advantage here is that the Antigen vaccine technology is entirely synthetic, making it simple to manufacture. In the event of a potentially pandemic influenza virus, there is clearly a need for this type of flexible vaccine technology that can be brought into production rapidly.

The distinguishing feature of Antigen Express technology (Ii-Key) is the ability to activate critical components of the immune system (CD4+ T helper cells) in a robust and specific manner. Currently this is a unique technology platform that directs proteins to a critical immune component to be able to create specific immune stimulation. This Ii-Key technology is proprietary to Antigen Express. Consequently, the Company is in a good position to license the technology for combination with multiple different target proteins to create novel vaccine applications that may be of interest to other researchers and companies.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavit
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
10. Generex Points to Potential of Antigen Express Technology Platform beyond Its AE37 Breast Cancer Vaccine
11. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... ALBANY, N.Y. , Oct. 20, 2014 ... pharmaceutical outsourcing facility in Albany, NY ... and trials. The company meets and/or exceeds the FDA ... 210 and 21 CFR Part 211. ... provide the highest levels of quality assurance and quality ...
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... , October 20, 2014 Shire plc ... Bowling , Interim Chief Financial Officer (CFO), has notified the Board ... role to pursue a new career opportunity as CFO of Severn ... 2015 and the company will commence a search for a new ... "James has helped build and lead a high-quality finance ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... N.J., Aug. 17 Palatin Technologies, Inc. (NYSE ... results of a Phase 1 clinical trial of ... for treatment of male erectile dysfunction (ED) and ... with subcutaneous administration consistent therapeutic blood plasma levels ...
... Aug. 17 Eli Lilly and Company (NYSE: ... gamma secretase inhibitor being studied as a potential treatment ... long-term Phase III studies showed it did not slow ... measures of cognition and the ability to perform activities ...
Cached Medicine Technology:Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men 4Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials 2Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials 3Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials 4Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials 5
(Date:10/20/2014)... San Diego, CA (PRWEB) October 20, 2014 ... regarding all the latest information from the FDA on ... consumers on October 10 not to purchase or use Sit ... Phenolphthalein. Sit and Slim II is promoted as weight loss ... , Sibutramine, removed from the market in 2010 for safety ...
(Date:10/20/2014)... National Teen Driver Safety Week is October ... of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the ... teen drivers to talk to their teens and always set ... crashes are the leading cause of death for U.S. teens. ... crashes, and 859 (42%) of those teen drivers were killed ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 Houston ... to present the key elements of his innovative ... professor to plastic surgery residents and faculty at ... , where he, too, was once a medical student. ... the largest private cosmetic plastic surgery practices in Texas, ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... 2014 SweetDressy.com, a professional company of ... promotion for long evening dresses . All the ... offer; the current discount is up to 66 percent ... pioneers in the fashion field. Its dress specialists are ... in various parts of the world. All the company’s ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... HealthDay Reporter , TUESDAY, Oct. 5 (HealthDay News) ... only protect themselves throughout their pregnancy but may also help ... of life. A study published online Oct. 4 ... found that when women were vaccinated in the second or ...
... that sucks up dangerous plaque debris could trigger a "paradigm ... in the current issue of Endovascular Today . ... write Dr. Robert Dieter of Loyola University Health System and ... clinical trials totaling 123 patients, the device had a success ...
... Scott & White Cancer Center,s Breast Cancer Clinic program ... National Accreditation Program for Breast Centers (NAPBC), a program ... Scott & White breast cancer is managed by a ... in excellent care," said Christopher O. Ruud, M.D., director ...
... Madonna Behen HealthDay Reporter , TUESDAY, Oct. ... help doctors one day identify which patients with mild ... Swiss researchers report. Using a combination of specialized ... University Hospitals of Geneva said they were able to ...
... be an efficient alternative when common drugs do not ... animals such as mice could not be used: The ... them. In an international cooperation, scientists from the Helmholtz ... now succeeded in developing a promising approach to solve ...
... most toxic free radical appears responsible for much of ... in the critically ill or injured, Medical College of ... and oxygen chambers used to significantly increase oxygen levels ... powerful enough to break down DNA and cause proteins ...
Cached Medicine News:Health News:Mom's Flu Shot May Protect Baby After Birth 2Health News:Mom's Flu Shot May Protect Baby After Birth 3Health News:'Paradigm shift' in how physicians treat peripheral artery disease 2Health News:Scott & White breast cancer program receives accreditation 2Health News:Computer-Aided MRI Might Help Predict Alzheimer's 2Health News:Computer-Aided MRI Might Help Predict Alzheimer's 3Health News:Mice with human body's defenses 2Health News:Powerful free radical causes lung damage from oxygen therapy 2
... Monitoring (IOM). Minimize risks during ... nervous system. Time-stamped event notation, data ... visual overview of the case using ... software allows simultaneous frequency analysis of ...
... Cadwell Cascade is a powerful, multi-modality system capable ... EMG, stimulated EMG, EEG, and train of four ... portability as a priority. The base weighs only ... just 13 lbs. A desktop PC-based system with ...
... monitoring system has been designed by ... needs of the ever changing and ... and analyzing data from multiple modalities, ... EEG and multiple patients at multiple ...
... Simultaneous,16 channel, multimodality EEG, EP and EMG ... fast response time. Simultaneously view vital signs, ... correlate neurological responses with systemic changes. Monitor, ... time without loss of data. Compact and ...
Medicine Products: